Dalia
Dalia Argaman, Hod-Hasharon IL
Patent application number | Description | Published |
---|---|---|
20080200838 | WEARABLE, PROGRAMMABLE AUTOMATED BLOOD TESTING SYSTEM - The present invention is a programmable, automated device for measurement and analysis of blood analytes and blood parameters. The device components are preferably combined in a single housing and either programmed to initiate automatic, periodic blood sampling or initiate automatic blood sampling via operator input or in response to a predefined event or in response to a signal from another instrument. The device operates automatically to draw blood samples and analyze the drawn blood samples to obtain the desired blood readings. | 08-21-2008 |
20080275324 | Fluid Access Interface - The present invention relates generally to systems, apparatuses, and methods for obtaining a fluid sample from a patient. In particular, the present invention relates to a various types of fluid access interfaces for enabling contact between a patient blood sample and blood parameter sensors for the measurement of physiological parameters and blood constituents. | 11-06-2008 |
20090156922 | BLOOD MONITORING SYSTEM - The present invention is directed towards apparatuses and methods for the automated measurement of blood analytes and blood parameters for bedside monitoring of patient blood chemistry. Particularly, the current invention discloses a programmable system that can automatically draw blood samples at a suitable programmable time frequency (or at predetermined timing), can automatically analyze the drawn blood samples and immediately measure and display blood parameters such as glucose levels, hematocrit levels, hemoglobin blood oxygen saturation, blood gases, lactate or any other blood parameter. | 06-18-2009 |
20120108936 | FLUID ACCESS INTERFACE - The present invention relates generally to systems, apparatuses, and methods for obtaining a fluid sample from a patient. In particular, the present invention relates to a various types of fluid access interfaces for enabling contact between a patient blood sample and blood parameter sensors for the measurement of physiological parameters and blood constituents. | 05-03-2012 |
Dalia Barsyte, Stouffville CA
Patent application number | Description | Published |
---|---|---|
20120128695 | TENEURIN C-TERMINAL ASSOCIATED PEPTIDES (TCAP) AND METHODS AND USES THEREOF - The invention provides a novel family of biologically active neuropeptides and the nucleic aid molecules coding for same. The peptides are derived for the C-terminus of the teneurin family peptides (Ten M1-4). These novel peptides, referred to as teneurin C-terminal associated peptides (TCAPs) are active in neuronal communication and are implicated in a number of neuropathologies. They are particularly useful in modulating stress responses and anxiety and in the treatment of cancer. | 05-24-2012 |
Dalia Burzyn, Cambridge, MA US
Patent application number | Description | Published |
---|---|---|
20140112898 | UNIQUE POPULATION OF REGULATORY T CELLS THAT REGULATE TISSUE REGENERATION AND WOUND HEALING - A unique type of regulatory T cell has been identified in muscle. These tissue-regenerative Treg cells play a role in regulating wound healing. These cells, as well as agents that control their differentiation and/or activity and agents produced by the cells, can be used to modulate wound healing and the differentiation of muscle cells. | 04-24-2014 |
Dalia Eicken, Houston, TX US
Patent application number | Description | Published |
---|---|---|
20110259355 | PERSONAL CARE PRODUCTS - A hair care product comprising water, a chelating agent, a copolymer, a pH adjusting agent and a hair treatment composition including a polyvinyl alcohol, polyvinyl alcohol copolymer, vinyl acetate emulsion, acrylic emulsion, vinyl acrylic emulsion, vinyl acetate copolymer emulsion or a combination thereof. | 10-27-2011 |
Dalia El-Sherif, King Of Prussia, PA US
Patent application number | Description | Published |
---|---|---|
20090196827 | Drug Loaded Contrast Agents: Combining Diagnosis and Therapy - This invention provides an improvement to methods of drug loading of ultrasound contrast agents. Echogenic drug-loaded polymer microcapsules, nanocapsules, or mixtures thereof produced by the method of the invention wherein the echogenic drug-loaded polymer microcapsules, nanocapsules, or mixtures thereof contain at least 10% more of a drug as compared to (1) echogenic drug-loaded polymer microcapsules, nanocapsules, or mixtures thereof prepared by adding drug prior to emulsifying or (2) echogenic drug-loaded polymer microcapsules, nanocapsules, or mixtures thereof prepared by adding drug to lyophilized polymer microcapsules, nanocapsules, or mixtures thereof. | 08-06-2009 |
20110125079 | Echogenic Polymer Microcapsules and Nanocapsules and Methods for Production and Use Thereof - Methods for producing echogenic polymer microcapsules and nanocapsules for use in diagnostic imaging and delivery of bioactive compounds as well as targeted imaging and delivery to selected tissues and cells are provided. Compositions containing these echogenic polymer microcapsules and nanocapsules for use in diagnostic imaging and delivery of bioactive agents are also provided. | 05-26-2011 |
20140213702 | Precursors to Echogenic Polymer Microcapsules or Nanocapsules - One aspect of the invention provides a precursor to an echogenic polymer microcapsule or nanocapsule. The precursor includes an emulsion including a polymer solution and an aqueous solution including a water-soluble sublimable solute. This aspect of the invention can have a variety of embodiments. In one embodiment, the water-soluble sublimable solute can be an ammonium salt. For example, the ammonium salt can be ammonium carbonate. | 07-31-2014 |
Dalia Jayes, Modiin IL
Patent application number | Description | Published |
---|---|---|
20090123826 | METHOD OF MAKING A THIN LAYER ELECTROCHEMICAL CELL WITH SELF-FORMED SEPARATOR - A method of forming an electrochemical cell is disclosed. The method comprises contacting a negative pole layer and a positive pole layer one with the other or with an optional layer interposed therebetween. The pole layers and the optional layer therebetween are selected so as to self-form an interfacial separator layer between the pole layers upon such contacting. | 05-14-2009 |
20100168233 | TERBINAFINE FORMULATION - The present invention provides a pharmaceutical composition comprising as the active agent a terbinafine compound, water, and at least one water-soluble or water-miscible nonionic surfactant, wherein the terbinafine compound has at least one form selected from the group consisting of free base form, acid addition salt form, ionic form, and combinations thereof; and wherein substantially no alcohol is present. | 07-01-2010 |
20100222734 | Double-sided patch - The present invention provides a double-sided patch comprising a first side and a second side, wherein each of the first side and the second side of the double-sided patch is configured as a treatment patch. Furthermore, the present invention provides a double-sided patch, wherein each side of the double-sided patch shares at least one common patch component with the other side of the double-sided patch. | 09-02-2010 |
20100228180 | Power Source Electrode Treatment Device - The present invention provides a powered treatment device comprising at least one power source for supplying electrical energy to the device, and wherein at least one component of the power source is also configured as a power source treatment device electrode to facilitate electrical contact with a body region. In an embodiment wherein one component of the power source is configured as a power source treatment device electrode, the powered treatment device may further comprise at least one non-power source device electrode of opposite polarity from the power source treatment device electrode, wherein the at least one non-power source device electrode is electrically coupled to the at least one power source to facilitate electrical contact with a body area. | 09-09-2010 |
Dalia Kalabat, El Cajon, CA US
Patent application number | Description | Published |
---|---|---|
20080261824 | Rationale, methods, and assays for identifying novel taste cell genes and salty taste receptor targets and assays using these identified genes or gene products - This invention relates to novel rationale and methods for identifying taste-specific genes, including genes involved in salty taste perception, especially human salty taste perception, but also genes involved in sweet, bitter, umami, and sour taste perception, and genes involved in other taste cell or taste receptor related activities such as digestive function and digestive related diseases, taste cell turnover, immunoregulation of the oral and digestive tract, and metabolic regulation such as in diabetes and obesity, the genes identified using these methods, and assays for identifying taste modulators (enhancers or blockers) and potential therapeutics using these genes. These compounds have potential application in modulating (enhancing or blocking) taste perception, especially salty taste perception and as potential therapeutics. In addition, this invention relates to novel methods for identifying taste-specific genes that can be used as markers for different taste cell types, including sweet, bitter, umami, sour, salt, and other taste cells in mammals as well as assays that measure the activity of the sweet, bitter, umami, or sour receptor in the presence of these genes to identify modulators of sweet, bitter, umami, and sour taste and to identify therapeutics especially for treating digestive or metabolic disorders, taste loss, and oral infections. Further, the invention provides specific methods of purifying, enriching, isolating or marking desired taste cell subtypes or lineages such as sweet, umami, bitter, salty, sour, fat or stem cells et al. e.g., by use of FACS, magnetic beads or other selection methods that purify, enrich, mark, or eliminate such as by use of labeled cytotoxins, cells that express or do not express one or more taste specific genes. | 10-23-2008 |
20090117563 | Identification of TRPML3 (MCOLN3) as a Salty Taste Receptor and Use in Assays for Identifying Taste (Salty) Modulators and/or Therapeutics that Modulate Sodium Transport, Absorption or Excretion and/or Aldosterone and/or Vasopressin Production or Release - This invention relates to the elucidation that TRPML3 is involved in salty taste perception in primates including humans and likely other mammals (given the significance of sodium and other ions to physiological functions and conditions this phenotype is likely strongly conserved in different animals). The invention also relates to the discovery that the TRPML3 gene also modulates one or more of sodium metabolism, sodium excretion, blood pressure, fluid retention, cardiac function and urinary functions such as urine production and excretion. The invention also relates to transgenic animals that have been engineered to express or knock out TRPML3 expression and assays using TRPML3 expressing animals, cells and isolated ion channel polypeptides for identifying compounds that modulate TRPML3-associated functions including salty taste, sodium metabolism, sodium excretion, blood pressure, fluid retention, cardiac function and urinary functions such as urine production and excretion. | 05-07-2009 |
20090208946 | Rationale, Methods, and Assays for Identifying Human and Non-Human Primate Taste Specific Genes and Use Thereof in Taste Modulator and Therapeutic Screening Assays - This invention relates to novel rationale and methods for identifying human and primate taste-specific genes, including genes involved in salty taste perception, especially human salty taste perception, but also genes involved in sweet, bitter, umami, and sour taste perception, and genes involved in other taste cell or taste receptor related activities such as digestive function and digestive related diseases, taste cell turnover, immunoregulation of the oral and digestive tract, and metabolic regulation such as in diabetes and obesity, the genes identified using these methods, and assays for identifying taste modulators (enhancers or blockers) and potential therapeutics using these genes. These compounds have potential application in modulating (enhancing or blocking) taste perception, especially salty taste perception and as potential therapeutics. In addition, this invention relates to novel methods for identifying taste-specific genes that can be used as markers for different taste cell types, including sweet, bitter, umami, sour, salty, and other taste cells in mammals as well as assays that measure the activity of the sweet, bitter, umami, or sour receptor in the presence of these genes to identify modulators of sweet, bitter, umami, and sour taste and to identify therapeutics especially for treating digestive or metabolic disorders, taste loss, and oral infections. Particularly, the genes identified herein and antibodies or oligos thereto can be used as markers to identify and/or purify specific taste cells e.g., from taste cell suspensions by use of FACS or magnetic bead cell selection or other known cell purification and isolation procedures. | 08-20-2009 |
20090210953 | Identification of TRPML3 (MCOLN3) as a salty taste receptor and use in assays for identifying taste (salty) modulators and/or therapeutics that modulate sodium transport, absorption or excretion and/or aldosterone, and/or vasopressin production or release - The present invention relates to the elucidation that TRPML3 is involved in salty taste perception in primates including humans and likely other mammals and based thereon high-throughput mammalian and medium-throughput oocyte-based electrophysiological assays for identifying human TRPML3 modulators, preferably TRPML3 enhancers. Compounds that modulate TRPML3 function in the assay are expected to affect salty taste in humans. The inventive electrophysiological assays, such as the two-electrode voltage-clamp technique, facilitate the identification of compounds which specifically modulate human TRPML3. The assays of the invention provide a robust screen useful to detect compounds that facilitate (enhance) or inhibit TRPML3 function. Compounds that enhance or block TRPML3 channel activity should thereby modulate salty taste. In addition, these compounds may be used to regulate sodium excretion, urinary output and other biological functions relating to sodium levels and TRPML3 related functions. | 08-20-2009 |
20100291125 | ETA-1 GENE AND METHODS FOR USE - The present application relates to osteopontin (Eta-1) polypeptides, nucleic acids that encode Eta-1, antibodies that specifically bind to Eta-1, and methods for enhancing an immune response in an animal. | 11-18-2010 |
20110281753 | RATIONALE, METHODS, AND ASSAYS FOR IDENTIFYING HUMAN AND NON-HUMAN PRIMATE TASTE SPECIFIC GENES AND USE THEREOF IN TASTE MODULATOR AND THERAPEUTIC SCREENING ASSAYS - This invention relates to novel rationale and methods for identifying human and primate taste-specific genes, including genes involved in salty taste perception, especially human salty taste perception, but also genes involved in sweet, bitter, umami, and sour taste perception, and genes involved in other taste cell or taste receptor related activities such as digestive function and digestive related diseases, taste cell turnover, immunoregulation of the oral and digestive tract, and metabolic regulation such as in diabetes and obesity, the genes identified using these methods, and assays for identifying taste modulators (enhancers or blockers) and potential therapeutics using these genes. These compounds have potential application in modulating (enhancing or blocking) taste perception, especially salty taste perception and as potential therapeutics. In addition, this invention relates to novel methods for identifying taste-specific genes that can be used as markers for different taste cell types, including sweet, bitter, umami, sour, salty, and other taste cells in mammals as well as assays that measure the activity of the sweet, bitter, umami, or sour receptor in the presence of these genes to identify modulators of sweet, bitter, umami, and sour taste and to identify therapeutics especially for treating digestive or metabolic disorders, taste loss, and oral infections. Particularly, the genes identified herein and antibodies or oligos thereto can be used as markers to identify and/or purify specific taste cells e.g., from taste cell suspensions by use of FACS or magnetic bead cell selection or other known cell purification and isolation procedures. | 11-17-2011 |
20140206004 | RATIONALE, METHODS, AND ASSAYS FOR IDENTIFYING HUMAN AND NON-HUMAN PRIMATE TASTE SPECIFIC GENES AND USE THEREOF IN TASTE MODULATOR AND THERAPEUTIC SCREENING ASSAYS - This invention relates to novel rationale and methods for identifying human and primate taste-specific genes, including genes involved in salty taste perception, especially human salty taste perception, but also genes involved in sweet, bitter, umami, and sour taste perception, and genes involved in other taste cell or taste receptor related activities such as digestive function and digestive related diseases, taste cell turnover, immunoregulation of the oral and digestive tract, and metabolic regulation such as in diabetes and obesity, the genes identified using these methods, and assays for identifying taste modulators (enhancers or blockers) and potential therapeutics using these genes. These compounds have potential application in modulating (enhancing or blocking) taste perception, especially salty taste perception and as potential therapeutics. In addition, this invention relates to novel methods for identifying taste-specific genes that can be used as markers for different taste cell types, including sweet, bitter, umami, sour, salty, and other taste cells in mammals as well as assays that measure the activity of the sweet, bitter, umami, or sour receptor in the presence of these genes to identify modulators of sweet, bitter, umami, and sour taste and to identify therapeutics especially for treating digestive or metabolic disorders, taste loss, and oral infections. Particularly, the genes identified herein and antibodies or oligos thereto can be used as markers to identify and/or purify specific taste cells e.g., from taste cell suspensions by use of FACS or magnetic bead cell selection or other known cell purification and isolation procedures. | 07-24-2014 |
Dalia Maidan-Hanoch, Kfar Yona IL
Patent application number | Description | Published |
---|---|---|
20090076270 | Drying process for preparing crystalline solid famciclovir - The present invention provides a drying process for preparing crystalline solid famciclovir form I comprising the steps of: i) preparing a wet crystalline form of famciclovir; ii) drying the wet crystalline form of famciclovir at a temperature of below 50° C. until the crystalline form contains less than 15% (wt/wt) wetness; and iii) drying the wet crystalline form of famciclovir at a temperature of above 50° C. until the wet crystalline form of famciclovir contains less than 0.05% (wt/wt) water to obtain crystalline solid famciclovir form I. | 03-19-2009 |
20090143459 | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms - The present invention provides novel forms of atorvastatin designated Forms VI, VII, VIII, IX, IXa, X, XI, XII, XIV, XVI and XVII and novel processes for their preparation as well as processes for preparing atorvastatin Forms I, II, IV, V and amorphous atorvastatin. | 06-04-2009 |
20090215806 | Rosuvastatin calcium with a low salt content - Provided is rosuvastatin calcium with a low salt by product content and processes for preparing such rosuvastatin calcium. | 08-27-2009 |
20090240054 | Rosuvastatin calcium with a low salt content - Provided is rosuvastatin calcium with a low salt by product content and processes for preparing such rosuvastatin calcium. | 09-24-2009 |
Dalia Megiddo, M.p. Judean Hills IL
Patent application number | Description | Published |
---|---|---|
20120277270 | Method for Decreasing Symptoms of Alcohol Consumption - The present invention relates to methods and compositions of metadoxine and physiologically compatible active derivatives thereof, and their use for decreasing symptoms of alcohol consumption as well as in the prevention of alcohol consumption related symptoms in subjects in need thereof. | 11-01-2012 |
20130012549 | Method for the Treatment, Alleviation of Symptoms of, Relieving, Improving and Preventing a Cognitive Disease, Disorder or Condition - The present invention provides uses of a salt adduct comprising at least one positively charged moiety being a pyridoxine or a derivative thereof and at least one carboxylated 5- to 7-membered lactam ring, optionally additionally substituted, for the preparation of a medicament for the treatment, alleviation of symptoms of, relieving, improving and preventing a cognitive disease, disorder or condition in a subject. Additionally, the invention provides use of said salt adducts for the preparation of medicaments for the improvement of cognitive functions in a healthy subject. | 01-10-2013 |
20150073023 | Method Of Treating Fragile X Syndrome And Related Disorders - The present invention provides methods of alleviating a sign or a symptom of Fragile X Syndrome and relates disorders such as autism spectrum disorders | 03-12-2015 |
20150209338 | METHOD FOR DECREASING SYMPTOMS OF ALCOHOL CONSUMPTION - The present invention relates to methods and compositions of metadoxine and physiologically compatible active derivatives thereof, and their use for decreasing symptoms of alcohol consumption as well as in the prevention of alcohol consumption related symptoms in subjects in need thereof. | 07-30-2015 |
20150335629 | Methods Of Treating Fragile X Syndrome And Related Disorders - The present invention provides methods of alleviating a sign or a symptom of Fragile X Syndrome and related disorders such as autism spectrum disorders. | 11-26-2015 |
Dalia Megiddo, Nataf IL
Patent application number | Description | Published |
---|---|---|
20110294859 | SUBSTITUTED PYRIDOXINE-LACTAM CARBOXYLATE SALTS - The present invention provides salt adducts comprising at least one positively charged moiety being a pyridoxine or a derivative thereof and at least one carboxylated 5- to 7-membered lactam ring, optionally additionally substituted, methods of their preparation, and pharmaceutical compositions and medicaments comprising them. Salt adducts of the invention and compositions comprising them may be used to in the treatment of diseases or disorders associated with or inflicted by alcohol consumption. | 12-01-2011 |
20120264781 | METHOD FOR THE TREATMENT, ALLEVIATION OF SYMPTOMS OF, RELIEVING, IMPROVING AND PREVENTING A COGNITIVE DISEASE, DISORDER OR CONDITION - The present invention provides uses of a salt adduct comprising at least one positively charged moiety being a pyridoxine or a derivative thereof and at least one carboxylated 5- to 7-membered lactam ring, optionally additionally substituted, for the preparation of a medicament for the treatment, alleviation of symptoms of relieving, improving and preventing a cognitive disease, disorder or condition in a subject. Additionally, the invention provides use of said salt adducts for the preparation of medicaments for the improvement of cognitive functions in a healthy subject. | 10-18-2012 |
20130059887 | SUBSTITUTED PYRIDOXINE-LACTAM CARBOXYLATE SALTS - The present invention provides salt adducts comprising at least one positively charged moiety being a pyridoxine or a derivative thereof and at least one carboxylated 5- to 7-membered lactam ring, optionally additionally substituted, methods of their preparation, and pharmaceutical compositions and medicaments comprising them. Salt adducts of the invention and compositions comprising them may be used to in the treatment of diseases or disorders associated with or inflicted by alcohol consumption. | 03-07-2013 |
20140336145 | COMPOSITIONS AND METHODS FOR TREATING OCULOPHARYNGEAL MUSCULAR DYSTROPHY - The present invention provides intravenous compositions of trehalose for the treatment of signs and symptoms of oculopharyngeal muscular dystrophy (OPMD). | 11-13-2014 |
20150025111 | SUBSTITUTED PYRIDOXINE-LACTAM CARBOXYLATE-SALTS - The present invention provides salt adducts comprising at least one positively charged moiety being a pyridoxine or a derivative thereof and at least one carboxylated 5- to 7-membered lactam ring, optionally additionally substituted, methods of their preparation, and pharmaceutical compositions and medicaments comprising them. Salt adducts of the invention and compositions comprising them may be used to in the treatment of diseases or disorders associated with or inflicted by alcohol consumption, | 01-22-2015 |
20150196575 | COMPOSITIONS AND METHODS FOR TREATING SPINOCEREBELLAR ATAXIA - The present invention provides intravenous compositions of trehalose for the treatment of signs and symptoms of spinocerebellar ataxia (SCA). | 07-16-2015 |
20150328247 | AGENTS FOR TREATING GENETIC DISEASES RESULTING FROM NONSENSE MUTATIONS, AND METHODS FOR IDENTIFYING THE SAME - Disclosed is treatment of genetic neurodegenerative or neurodevelopmental diseases that are caused by or associated with nonsense mutations or premature termination codons using macrolides. Further disclosed are methods for identifying agents that induce read-through of nonsense mutations and premature termination codons and uses thereof. | 11-19-2015 |
Dalia Rav David, Nes Tziona IL
Patent application number | Description | Published |
---|---|---|
20150351392 | MELANOIDINS AND THEIR USE FOR IMPROVING PROPERTIES OF PLANTS - The present invention relates to melanoidins and their use for improving properties of plants. The methods and compositions of the invention are particularly useful for control of fungal plant diseases and drought conditions, and promotion of plant growth. | 12-10-2015 |
Dalia Reznitsky-Cohen, Nes Ziona IL
Patent application number | Description | Published |
---|---|---|
20110105607 | LIPOPHILIC DIESTERS OF CHELATING AGENT FOR INHIBITION OF ENZYME ACTIVITY - The present invention relates to the use of lipophilic diesters of the chelating agent 1,2-bis(2 aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid (BAPTA) for inhibition of proteolytic activities of certain metalloproteinases, calpain and TACE | 05-05-2011 |
Dalia Shallom-Shezifi, Kibbutz Nasholim IL
Patent application number | Description | Published |
---|---|---|
20150352136 | NOVEL AMINOGLYCOSIDES AND USES THEREOF IN THE TREATMENT OF GENETIC DISORDERS - A new class of paromomycin-derived aminoglycosides, which exhibit efficient stop-codon mutation suppression activity, low toxicity and high selectivity towards eukaryotic cells are provided. Also provided are chemical and chemo-enzymatic processes of preparing these paromomycin-derived aminoglycosides and intermediates thereof, as well as pharmaceutical compositions containing the same, and uses thereof in the treatment of genetic disorders. | 12-10-2015 |
Dalia Shallom-Shezifi, Haifa IL
Patent application number | Description | Published |
---|---|---|
20090093418 | Novel aminoglycosides and uses thereof in the treatment of genetic disorders - A new class of paromomycin-derived aminoglycosides, which exhibit efficient stop-codon mutation suppression activity, low toxicity and high selectivity towards eukaryotic cells are provided. Also provided are chemical and chemo-enzymatic processes of preparing these paromomycin-derived aminoglycosides and intermediates thereof, as well as pharmaceutical compositions containing the same, and uses thereof in the treatment of genetic disorders. | 04-09-2009 |
Dalia Somjen, Rehovot IL
Patent application number | Description | Published |
---|---|---|
20100029758 | DERIVATIVES OF ISOFLAVONES - The present invention discloses novel isoflavone conjugates and their use for affinity targeting of drugs, imaging and detection agents to cells having estrogen receptors, particularly estrogen receptors subtype β. | 02-04-2010 |
20100069478 | ISOFLAVONE DERIVATIVES AND USES THEREOF - Isoflavone derivatives are provided comprising a carboxyalkylene moiety linked via its alkylene chain to the aromatic ring and via its carboxy group to an aminoalkyleneamino residue, which, in turn, is covalently linked to a functional group B. The isoflavone derivatives are preferably derived from biochanin A, genistein, and daidzein, and the functional group B is preferably an amino protecting group. These isoflavone derivatives are useful for treating or preventing diseases or disorders associated with estrogen receptor functioning. | 03-18-2010 |
Dalia Vishnudasan, Victoria AU
Patent application number | Description | Published |
---|---|---|
20090191636 | Method of Producing Transgenic Graminaceous Cells and Plants - The present invention provides a method for producing a transgenic graminaceous plant cell, said method comprising: (i) obtaining embryonic cells from a mature graminaceous grain; and (ii) contacting said embryonic cells with a bacterium capable of transforming a plant cell, said bacterium comprising transfer-nucleic acid to be introduced into the embryonic cells, said contacting being for a time and under conditions sufficient for said bacterium to introduce said transfer-nucleic acid into one or more of the embryonic cells, thereby producing a transgenic graminaceous plant cell. The present invention also provides a method for producing a transgenic graminaceous plant. The present invention also provides a transgenic graminaceous plant cell and/or a transgenic graminaceous plant produced by said method. The present invention also provides a method for expressing a nucleic acid in a transgenic graminaceous plant cell or a transgenic graminaceous plant. | 07-30-2009 |